Author
|
Year
|
No. of patients randomized
|
No. of patients receiving intervention
|
No. of patients receiving comparison
|
Trial duration (weeks)
|
Intervention
|
Comparator
|
Risk of bias* selection/performance/attrition/reporting
|
---|
Dougados
|
1986
|
30
|
15
|
15
|
26
|
SSZ (P)
|
PL
|
A/A/A/A
|
Feltelius
|
1986
|
37
|
18
|
19
|
12
|
SSZ (P)
|
PL
|
U/U/A/A
|
Nissila
|
1988
|
85
|
43
|
42
|
26
|
SSZ (P)
|
PL
|
U/U/A/A
|
Davis
|
1989
|
30
|
15
|
15
|
12
|
SSZ (P)
|
PL
|
U/U/A/A
|
Kraag
|
1989
|
53
|
26
|
27
|
16
|
Supervised training (NP)
|
SC
|
U/U/I/A
|
Winkler
|
1989
|
63
|
31
|
32
|
24
|
SSZ (P)
|
PL
|
U/U/U/A
|
Corkill
|
1990
|
62
|
32
|
30
|
48
|
SSZ (P)
|
PL
|
A/A/I/A
|
Krajnc
|
1990
|
95
|
71
|
24
|
24
|
SSZ (P)
|
PL
|
U/U/A/A
|
Taylor
|
1991
|
40
|
20
|
20
|
52
|
SSZ (P)
|
PL
|
A/A/A/I
|
Hidding
|
1993
|
144
|
68
|
76
|
36
|
Group physiotherapy (NP)
|
AC
|
A/A/I/A
|
Kirwan
|
1993
|
89
|
44
|
45
|
156
|
SSZ (P)
|
PL
|
A/A/A/I
|
Dougados
|
1994
|
70
|
46
|
24
|
12
|
Ximoprofen 5 mg (P)
|
PL
|
A/A/U/A
|
1994
|
73
|
49
|
24
|
34
|
Ximoprofen 10 mg (P)
|
PL
|
A/A/U/A
|
1994
|
69
|
45
|
24
|
8
|
Ximoprofen 20 mg (P)
|
PL
|
A/A/U/A
|
1994
|
74
|
50
|
24
|
6
|
Ximoprofen 30 mg (P)
|
PL
|
A/A/U/A
|
Clegg
|
1996
|
264
|
131
|
133
|
36
|
SSZ (P)
|
PL
|
U/U/A/A
|
Helliwell
|
1996
|
22
|
15
|
7
|
44
|
In-patient physiotherapy (NP)
|
SC
|
I/I/I/A
|
1996
|
22
|
15
|
7
|
44
|
Out-patient hydrotherapy (NP)
|
SC
|
I/I/I/A
|
Dougados
|
1999
|
148
|
108
|
40
|
6
|
Piroxicam (P)
|
PL
|
U/U/A/A
|
1999
|
160
|
120
|
40
|
6
|
Meloxicam 15 mg (P)
|
PL
|
U/U/A/A
|
1999
|
164
|
124
|
40
|
6
|
Meloxicam 22.5 mg (P)
|
PL
|
U/U/A/A
|
Altan
|
2001
|
51
|
26
|
25
|
52
|
MTX (P)
|
AC
|
U/U/I/I
|
Dougados
|
2001
|
118
|
80
|
38
|
6
|
Celecoxib (P)
|
PL
|
U/U/U/A
|
2001
|
128
|
90
|
38
|
6
|
Ketoprofen (P)
|
PL
|
U/U/U/A
|
Van Tubergen
|
2001
|
120
|
80
|
40
|
3
|
Spa-exercise therapy (NP)
|
AC
|
A/A/I/A
|
Braun
|
2002
|
70
|
35
|
35
|
12
|
Infliximab (B)
|
PL
|
A/A/A/I
|
Gorman
|
2002
|
40
|
20
|
20
|
16
|
Etanercept (B)
|
PL
|
A/A/A/A
|
Roychowdhury
|
2002
|
30
|
14
|
16
|
24
|
MTX (P)
|
PL
|
U/U/A/A
|
Schmidt
|
2002
|
70
|
34
|
36
|
26
|
SSZ (P)
|
PL
|
U/U/U/A
|
Sweeney
|
2002
|
200
|
100
|
100
|
26
|
Supervised training (NP)
|
SC
|
U/U/I/A
|
Analay
|
2003
|
51
|
27
|
24
|
12
|
Supervised training (NP)
|
SC
|
A/A/I/A
|
Brandt
|
2003
|
33
|
16
|
17
|
6
|
Etanercept (B)
|
PL
|
A/A/A/I
|
Davis
|
2003
|
277
|
138
|
139
|
24
|
Etanercept (B)
|
PL
|
A/A/A/A
|
Calin
|
2004
|
84
|
45
|
39
|
12
|
Etanercept (B)
|
PL
|
U/U/A/A
|
Gonzalez-Lopez
|
2004
|
35
|
17
|
18
|
24
|
MTX (P)
|
PL
|
A/A/A/I
|
Codish
|
2005
|
28
|
14
|
14
|
12
|
Balneo therapy (NP)
|
AC
|
U/U/I/A
|
D’Las Penas
|
2005
|
40
|
20
|
20
|
16
|
Supervised training (NP)
|
SC
|
A/A/I/A
|
Lim
|
2005
|
50
|
25
|
25
|
8
|
Supervised training (NP)
|
SC
|
U/U/I/A
|
Marzo-Ortega
|
2005
|
42
|
28
|
14
|
30
|
Infliximab (B)
|
PL
|
A/A/U/A
|
Van der Heijde
|
2005
|
279
|
201
|
78
|
24
|
Infliximab (B)
|
PL
|
U/U/A/A
|
Van der Heijde
|
2005
|
134
|
103
|
31
|
6
|
Etoricoxib (P)
|
PL
|
A/A/A/A
|
2005
|
123
|
92
|
31
|
6
|
Etoricoxib (P)
|
PL
|
A/A/A/A
|
2005
|
130
|
99
|
31
|
6
|
Naproxen (P)
|
PL
|
A/A/A/A
|
Altan
|
2006
|
60
|
30
|
30
|
24
|
Balneo therapy (NP)
|
AC
|
U/U/I/A
|
Barkhuizen
|
2006
|
189
|
137
|
52
|
12
|
Celecoxib 200 mg (P)
|
PL
|
U/U/U/A
|
2006
|
213
|
161
|
52
|
12
|
Celecoxib 400 mg (P)
|
PL
|
U/U/U/A
|
2006
|
209
|
157
|
52
|
12
|
Naproxen (P)
|
PL
|
U/U/U/A
|
Ince
|
2006
|
30
|
15
|
15
|
12
|
Supervised training (NP)
|
SC
|
U/U/I/A
|
Van der Heijde
|
2006
|
315
|
208
|
107
|
24
|
Adalimumab (B)
|
PL
|
A/A/A/A
|
Van der Heijde
|
2006
|
180
|
155
|
25
|
24
|
Etanercept (B)
|
PL
|
U/U/U/A
|
2006
|
175
|
150
|
25
|
24
|
Etanercept (B)
|
PL
|
U/U/U/A
|
Lambert
|
2007
|
82
|
38
|
44
|
24
|
Adalimumab (B)
|
PL
|
U/U/A/A
|
Huang
|
2008
|
126
|
83
|
43
|
8
|
Etanercept (B)
|
PL
|
U/U/U/U
|
Inman
|
2008
|
177
|
138
|
39
|
14
|
Golimumab (B)
|
PL
|
A/A/A/A
|
2008
|
179
|
149
|
39
|
14
|
Golimumab (B)
|
PL
|
A/A/A/A
|
Barkham
|
2010
|
40
|
20
|
20
|
12
|
Etanercept (B)
|
PL
|
U/U/A/A
|
Inman
|
2010
|
76
|
39
|
37
|
12
|
Infliximab (B)
|
PL
|
U/U/U/A
|
Braun
|
2011
|
566
|
379
|
187
|
16
|
Etanercept (B)
|
AC
|
A/A/A/A
|
Dougados
|
2011
|
82
|
39
|
43
|
12
|
Etanercept (B)
|
PL
|
U/U/A/I
|
Navarro-Sarabia
|
2011
|
108
|
54
|
54
|
12
|
Etanercept (B)
|
AC
|
A/A/A/A
|
Hu
|
2012
|
46
|
26
|
20
|
12
|
Adalimumab (B)
|
PL
|
U/U/U/I
|
Bao
|
2014
|
213
|
108
|
105
|
24
|
Golimumab (B)
|
PL
|
U/U/U/A
|
Huang
|
2014
|
344
|
229
|
114
|
12
|
Adalimumab (B)
|
PL
|
A/A/A/A
|
- *Shown as selection bias (methods for sequence generation and allocation)/performance bias (blinding of participants and personnel)/attrition bias (incomplete outcome data)/reporting bias (selective outcome reporting). Abbreviations: SSZ sulfasalazine, P pharmacological modalities, PL placebo, NP non-pharmacological modalities, B biological modalities, SC standard care, AC active comparison, A adequate, U unclear, I inadequate